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Abstract
Background: There has been great interest in determining whether natural products show biological activity toward protein
targets of pharmacological relevance. One target of particular interest is DPP-IV whose most important substrates are
incretins that, among other beneficial effects, stimulates insulin biosynthesis and secretion. Incretins have very short half-
lives because of their rapid degradation by DPP-IV and, therefore, inhibiting this enzyme improves glucose homeostasis. As
a result, DPP-IV inhibitors are of considerable interest to the pharmaceutical industry. The main goals of this study were (a)
to develop a virtual screening process to identify potential DPP-IV inhibitors of natural origin; (b) to evaluate the reliability of
our virtual-screening protocol by experimentally testing the in vitro activity of selected natural-product hits; and (c) to use
the most active hit for predicting derivatives with higher binding affinities for the DPP-IV binding site.
Methodology/Principal Findings:We predicted that 446 out of the 89,165 molecules present in the natural products subset
of the ZINC database would inhibit DPP-IV with good ADMET properties. Notably, when these 446 molecules were merged
with 2,342 known DPP-IV inhibitors and the resulting set was classified into 50 clusters according to chemical similarity,
there were 12 clusters that contained only natural products for which no DPP-IV inhibitory activity has been previously
reported. Nine molecules from 7 of these 12 clusters were then selected for in vitro activity testing and 7 out of the 9
molecules were shown to inhibit DPP-IV (where the remaining two molecules could not be solubilized, preventing the
evaluation of their DPP-IV inhibitory activity). Then, the hit with the highest activity was used as a lead compound in the
prediction of more potent derivatives.
Conclusions/Significance: We have demonstrated that our virtual-screening protocol was successful in identifying novel
lead compounds for developing more potent DPP-IV inhibitors.
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Introduction
Type 2 diabetes mellitus (T2DM) is considered to be the
‘‘epidemic of the 21st century’’ and, consequently, the de-
velopment of new therapies is one of the main challenges in drug
discovery today [1]. While current T2DM therapies that increase
insulin secretion have proven to have beneficial therapeutic effects,
these treatments often suffer from undesirable side effects such as
hypoglycemia and weight gain [2]. Therefore, there is a significant
unmet medical need for better drugs to treat T2DM.
Recently, the inhibition of human dipeptidyl peptidase-IV
(DPP-IV; EC 3.4.14.5) has emerged as a new treatment option for
T2DM [3]. This enzyme belongs to the serine protease family and
selectively removes N-terminal dipeptides from substrates contain-
ing proline or alanine as the second residue. The most important
substrates of DPP-IV are incretins, such as glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
[4]. GLP-1 is released from intestinal L-cells in response to meals
and performs the following actions: GLP-1 stimulates insulin
biosynthesis and secretion, reduces glucagon release, slows gastric
emptying, reduces appetite, and stimulates the regeneration and
differentiation of islet B-cells [5]. Alternatively, GIP is produced by
the duodenal K-cells and is extensively involved in glucose
metabolism by enhancing insulin secretion [6]. Both peptides
have very short half-lives (4 min for GIP and only 1–2 min for
GLP-1) because of their rapid degradation by DPP-IV. Inhibiting
DPP-IV prolongs the action of GLP-1 and GIP, which, in turn,
improves glucose homeostasis with a lower risk of hypoglycemia.
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Consequently, DPP-IV inhibitors are of considerable interest to
the pharmaceutical industry [7], and intense research activities in
this area have resulted in the launch of sitagliptin, saxagliptin,
alogliptin, linagliptin and vildagliptin to the market [8].
The DPP-IV binding site is highly druggable in the sense that
tight and specific binding to the enzyme can be achieved with
small molecules with drug-like physicochemical properties [9,10].
The different interaction motifs used by these DPP-IV ligands
include Ser630 (that together with Asp708 and His740 form the
enzyme catalytic triad), the hydrophobic S1 pocket (formed by
Tyr631, Val656, Trp659, Tyr662, Tyr666 and Val711), the
hydrophobic S2 pocket (formed by Arg125, Phe357, Arg358,
Tyr547, Pro550 and Asn710) and the N-terminal recognition
region (formed by Glu205, Glu206 and Tyr662) [9,11]. Based on
the analysis of the DPP-IV crystal structures [12–18] and
interpretation of the structure-activity relationship (SAR) data,
both the lipophilic S1 pocket and the Glu205/Glu206 dyad can be
considered as crucial molecular anchors for DPP-IV inhibition [9].
The large scaffold diversity and properties of natural products
(NPs), such as structural complexity and drug similarity, makes
these molecules ideal starting points for drug design. The main
goal of this paper is to apply a virtual screening (VS) protocol to
identify NPs with DPP-IV inhibitory activity as well as different
scaffolds relative to known DPP-IV inhibitors that could be used as
lead compounds in drug-design. In order to achieve this goal, we
first identified complexes between DPP-IV and potent reversible
inhibitors of non-peptide nature in the PDB. After validating the
fit of the coordinates of binding site residues and inhibitors onto
the corresponding electron density map, the validated DPP-IV
complexes were overlapped to get the experimental poses of the
inhibitor in the same orientation. Subsequently, the relative
contribution of the different intermolecular interactions to the
protein-ligand binding affinity was quantified to derive structure-
based pharmacophores. The resulting energetically optimized
pharmacophores were used to derive a structure-based common
pharmacophore that contained key intermolecular interactions
between DPP-IV and the inhibitors. The exclusion volumes were
also determined and added to the pharmacophore. Then, the
previous structure-based pharmacophore and a VS protocol were
used to look for DPP-IV inhibitors in a NPs database [19], and the
reliability of the prediction was demonstrated using in vitro testing
to determine the DPP-IV inhibitory effects of representative VS
hits. Lastly, the hit with the highest activity was used as a lead
compound in a combinatorial screen for the prediction of more
potent DPP-IV inhibitors.
Results and Discussion
Common Structure-based Pharmacophore Building and
Description
There are currently 54 entries for DPP-IV in the Protein Data
Bank (PDB; http://www.pdb.org; see Table 1) [20] but only 10 of
those entries correspond to validated complexes of the native
enzyme with potent reversible inhibitors of a non-peptide nature
(see Figure 1). As a result, only these 10 entries are suitable for
deriving reliable structure-based pharmacophores that capture the
key intermolecular interactions needed for drugs to inhibit DPP-
IV. In order to define a common background for DPP-IV
inhibition, we identified features of inhibitors that make the most
important contributions to the bioactivity of the ligand by first
superposing all 10 PDB files. Then, the energetic pharmacophores
were derived from the resulting coordinates, and energetically
relevant pharmacophore sites were visually inspected for finding
common or frequent ones. Figure 2 shows that all 10
pharmacophores have two sites in common (one positive/donor
and one hydrophobic/aromatic ring) that often make the most
important contribution to the protein-ligand binding affinity (see
data for sites P/D and H/R1 in Table 2). From these data, we
inferred that these two sites are essential for the inhibition of DPP-
IV and considered them to be required in the common structure-
based pharmacophore (see Figure 3). Interestingly, previous
studies have identified the lipophilic S1 pocket (formed by
Tyr631, Val656, Trp659, Tyr662, Tyr666 and Val711) and the
Glu205/Glu206 dyad as crucial molecular anchors for inhibition
[9,21,22] and, in coherence with this, the mandatory hydropho-
bic/aromatic ring and positive/donor sites interact with the S1
pocket and Glu205/Glu206, respectively. Table 2 also shows that
there are two other hydrogen-bond acceptors (A1 and A2) and
three hydrophobic/aromatic ring sites (H/R2, H/R3 and H/
R4) that, although not common to all experimental poses, could
increase either protein-ligand binding affinity or drug-specificity.
Moreover, it is remarkable that these sites correspond to
interactions with other relevant areas from the DPP-IV binding
site. For example, the H/R2 site interacts with Phe357, Arg358
and Tyr547 in the S2 pocket (known to preferentially recognize
large hydrophobic and aromatic side chains [11]). Therefore, these
sites were also included as optional sites in the common structure-
based pharmacophore (see Figure 3).
VS Workflow Description and Application to the NP
Subset of the ZINC Database
The VS workflow (see Figure 4) consisted of several sequential
steps where the output molecules of one step were the input
molecules for the next step and so on. The NP subset of the ZINC
database was used as the source of molecules to which our VS
schema was applied to search for new DPP-IV inhibitors. Initially,
these 89,165 molecules were submitted to an ADME/Tox filter
with the FAF-Drugs2 tool [23] aimed at discarding molecules that
were either potentially toxic or exhibited poor ADME properties.
Conformers for molecules with appropriate ADME/Tox
properties were then filtered with Phase through the structure-
Table 1. Codes for DPP-IV structures currently available at
PDB.
Valid PDB Structures Discarted PDB Structures
1N1M 2OPH 2RIP (a) (b) (c) (d) (e)
2FJP 2OQI 3C43 1J2E 1TKR* 1R9N 1RWQ 1X70
2HHA 2OQV 3C45 1NU6 2AJL 1WCY 2BUB 2OAG
2I78 2P8S 3CCC 1NU8 2G5T 2BGN 2JID 3CCB
2IIT 2QJR 3D4L 1PFQ 2G5P 2BGR 3EIO
2IIV 2QOE 3F8S 1R9M 2G63
2OGZ 2QT9 3H0C 1TK3 2I03
2OLE 2QTB 3HAB 1U8E 2QKY
2ONC 2RGU 3HAC 1W1I 3BJM*
Some PDB structures were discarded for the following reasons: (a) the
structures were of apo forms without inhibitor, (b) inhibitors were covalently
linked with Ser630, (c) inhibitors were of oligopeptide nature, (d) there were no
structural factors available in the PDB or (e) the scripts in the EDS failed to
produce the map from the structural factors. PDB structures marked with an
asterisk (*) have mutations in the enzyme to modify the activity. Only the PDB
files from the ‘‘Valid PDB Structures’’ section with IC50 values #10 nM (in
bold) were used to derive the corresponding structure-based common
pharmacophore for DPP-IV inhibition (see Figure 1).
doi:10.1371/journal.pone.0044971.t001
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based common pharmacophore. Ligands with at least one hit in
the Phase search were then used in a protein-ligand rigid-
docking study and docked onto the ligand binding site of the
DPP-IV conformation present in the 3C45 PDB file [14]. In
order to find docking poses that were compatible with the
pharmacophore, the resulting ligand poses were filtered again
with Phase through the structure-based common pharmaco-
phore using the same filtering conditions as in the first Phase
run but without reorienting the poses (i.e., the score in place
option was used). From these two pharmacophore screens, we
obtained 4,952 compounds (see Figure 4) with at least one pose
that was both compatible with the DPP-IV active site and had
functional groups that match the 3D location of the two
compulsory sites and at least one of the optional sites of the
structure-based common pharmacophore.
Finally, the poses for the 4,952 compounds from the second
pharmacophore screen were submitted to a shape and electrostat-
ic-potential comparison with the experimental pose of the DPP-IV
inhibitor at the PDB file 3C45 (that has the smallest IC50 for all the
non-peptide reversible inhibitors found in DPP-IV-inhibitor
complexes at the PDB [14]; see Figure 1). The shape and
electrostatic-potential comparison identified 446 hit molecules
with potential DPP-IV inhibitory activity (see Figure 4).
Finding New Scaffolds of Natural Origin for DPP-IV
Inhibitors
One of the most important challenges of any VS workflow is the
ability to find molecules with the required activity but without
trivial similarity (in terms of chemical structure) to known active
compounds. To determine which of the 446 potential DPP-IV
inhibitors predicted by our VS workflow could be considered as
new lead molecules, we merged the 446 potential DPP-IV
inhibitors with 2,342 known DPP-IV inhibitors that were obtained
from the BindingDB database [24]. After calculating the 2D
fingerprints of these inhibitors, the resulting set was classified into
50 clusters by means of a hierarchical cluster analysis (data not
shown). Notably, 12 out of the 50 clusters obtained consisted
exclusively of NPs that were previously unidentified as DPP-IV
inhibitors. The 219 molecules that belong to these 12 clusters are
scaffold-hopping candidates for DPP-IV inhibition (see Table S1).
To prove the reliability of our predictions, we selected 9 molecules
(C1 and C2 from cluster 30, C3 from cluster 36, C4 from cluster
Figure 1. Drug-like reversible DPP-IV inhibitors used for the generation of the common structure-based pharmacophore with their
corresponding IC50 values. The codes of the PDB complexes from which the ligand poses were used are also shown.
doi:10.1371/journal.pone.0044971.g001
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37, C5 and C6 from cluster 41, C7 from cluster 45, C8 from
cluster 49 and C9 from cluster 50) from 7 of these 12 clusters (see
Figure 5) and tested their effects on the DPP-IV activity using an in
vitro assay. The results of this experiment demonstrated that 7 out
of the 9 molecules (C1, C2, C3, C5, C7, C8 and C9) inhibit DPP-
IV (see Figure 6). The remaining molecules, C4 and C6, could not
be solubilized, preventing the evaluation of their DPP-IV in-
hibitory activity. The lack of DPP-IV inhibitory activity for C5,
C7 and C9 at 1mM was also due to insolubility (see Figure 6).
Furthermore, Figure 6 shows that from all the tested molecules,
C5 is the most potent inhibitor with an IC50 of 61.55 mM (see
Figure 7). With the exception of C1, which significantly inhibited
DPP-IV only at 1 mM, the rest of the molecules significantly
inhibit DPP-IV at 0.25 mM (see Figure 6) showing a dose-
response effect. Moreover, a SciFinder search (Chemical Abstracts
Service, Columbus, Ohio, USA; http://www.cas.org/products/
sfacad) of the literature revealed that none of these 7 molecules
Figure 2. The relative location of the experimental poses of the ligands in Figure 1 after DPP-IV superposition. The experimental pose
for the most potent inhibitor (i.e., the one at 3C45) is shown in black for reference. For each ligand, the energetically relevant pharmacophore sites are
shown. Light red and light blue spheres represent the acceptor and donor features, respectively. The green spheres and orange torus display the
hydrophobic regions and aromatic rings, respectively. Blue spheres represent positively charged regions.
doi:10.1371/journal.pone.0044971.g002
Table 2. Site contribution to the energy-optimized pharmacophores obtained from PDB complexes in bold from Table 1.
PDB 2FJP 2IIT 2IIV 2QT9 2QTB 2RGU 3C45 3H0C 3HAB 3HAC
P/D 24,6 24,13 24,45 24,09 24,54 21,66 24,54 24,81 24,54 24,29
H/R1 0,77 21,29 21,36 21,25 21,68 20,075 20,64 21,18 21,1 21,25
H/R2 20,69 20,66 20,68 20,9 20,69
H/R3 21,94
H/R4 20,85
H/R5 20,56
A1 20,64 20,4 20,59
A2 20,62
A3 20,35 20,35
A4 20,44
Required and optional sites at the structure-based common pharmacophore are shown in bold and italics, respectively. The other sites are not part of the structure-
based common pharmacophore. Data at the same raw for different PDB complexes indicate that the pharmacophore site is shared by these complexes.
doi:10.1371/journal.pone.0044971.t002
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have been reported as antidiabetic drugs. In fact, no bioactivity
has been described for these 7 molecules.
Structural Analysis of the Inhibition of DPP-IV by C1, C2,
C3, C5, C7, C8 and C9
The docking of C1, C2, C3, C5, C7, C8 and C9 in the DPP-
IV binding site of the 3C45 structure demonstrated that these
molecules match the structure-based common pharmacophore in
the same orientation, sharing the same intermolecular interactions
with DPP-IV (see Figures 8 and 9A). With the exception of C7 in
which the positive charge of the tertiary amine forms a salt bridge
with Glu205/Glu206 (see Figure 8D), all compounds use primary
or secondary amines to form hydrogen bond interactions with
either Glu206 or with the Glu205/Glu206 dyad side chains (see
Figures 8 and 9A). Additionally, all molecules filled the S1 pocket
(partially in the case of C1 and C8, which could explain why these
two molecules have lower activities as DPP-IV inhibitors; see
Figure 6) establishing one intermolecular interaction that corre-
sponds to the compulsory H/R1 site of our common structure-
based pharmacophore (see Figure 3). Moreover, it is worthwhile to
mention that some molecules could potentially form additional
hydrogen bonds with DPP-IV. For example, the hydroxyl and the
methoxy groups of C1 could hydrogen bond with the side chains
of Glu206 and Ser630, respectively (see Figure 8A). C8 forms two
additional hydrogen bonds with the side chains of Arg358 and
Tyr666 (see Figure 8E). Finally, C9 could form three additional
hydrogen bonds with the side chains of Tyr547, Ser630 and
Tyr662 (see Figure 8F).
Figure 9A shows the best docking pose of C5 in the DPP-IV
binding pocket where its tertiary amine hydrogen bonds with
Glu206. The carbonyl oxygen of the 7-hydroxy-2H-chromen-2-
one moiety could also hydrogen bond with the Tyr666 side chain.
The S1 pocket is occupied by the C5 butyl chain that could form
hydrophobic interactions with Tyr662, Tyr666 and Val711.
Finally, the chromene ring of the 7-hydroxy-2H-chromen-2-one
moiety forms p-p interactions with Phe357. Interestingly, this
interaction with Phe357 has been shown to be directly related to
the increased potency of synthetic DPP-IV inhibitors relative to
those that lack this interaction [13,15,25–27]. Therefore, the fact
that this interaction is only present at C5 (see Figures 8 and 9A)
would explain why this molecule shows higher bioactivity than the
other compounds assayed (see Figure 6). Moreover, an electro-
static and shape comparison of the 7 poses in Figures 8 and 9A
revealed that the molecule with the highest similarity to the 3C45
ligand (with the lowest IC50; see Figure 1) is C5 (results not shown).
The ET_combo score for this comparison is 1.050, which
corresponds to a shape and electrostatic contribution of 0.628
and 0.422, respectively. Remarkably, the same analysis with C2
(which shows a significant bioactivity as DPP-IV inhibitor; see
Figure 6), also has a significant ET_combo score of 1.038.
Predicting ZINC02132035 Derivatives with Higher
Binding Affinity on DPP-IV
Although none of the seven in vitro assayed VS hits showed
activity in the nanomolar range, these hits incorporate scaffolds
with no previously described effects on DPP-IV activity and,
consequently, are of interest from a medicinal chemistry point of
view as lead compounds for more potent DPP-IV inhibitors. With
this goal in mind, we have predicted derivatives for the most
potent DPP-IV inhibitor found in our dose-response studies (i.e.,
Figure 3. The structure-based common pharmacophore derived from the alignment of the poses in Figure 2 and shown in the
context of the 3C45 active site. The pharmacophore is formed by two hydrogen-bond acceptors (i.e., A1 and A2), one positive/hydrogen-bond
donor feature (i.e., P/D) and 4 hydrophobic/aromatic ring sites (i.e., H/R1, H/R2, H/R3 and H/R4). The associated tolerances (i.e., radii) of the
pharmacophore are 1.8A˚ for P/D, A1 and A2, 2.0A˚ for H/R1, H/R3 and H/R4 and 3.3A˚ for H/R2. Two out of these seven sites (i.e., P/D and H/R1) are
required during pharmacophore-based searches whereas the remaining five are optional. The P/D site interacts with the Glu205/Glu206 dyad
whereas the H/R1 site potentially fills the S1 pocket. The residues are colored according to the type of intermolecular interactions involved. For
example, blue residues interact with donor sites, pink residues interact with acceptor sites and green residues are involved in hydrophobic contacts.
Light green residues are a part of the S1 pocket.
doi:10.1371/journal.pone.0044971.g003
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C5; see Figure 6) by (1) using a fragment-based docking approach
to identify which intermolecular interactions with the DPP-IV
binding site could improve the binding affinity of C5 derivatives
relative to C5; (2) using this information to identify where changes
in C5 should be made; and (3) accordingly building C5
derivatives and predicting their relative binding affinities.
The comparison of the XP descriptors from C5 and from the
docked poses of the fragments showed that while some of the terms
of the scoring function are 0.00 Kcal/mol for C5, their
corresponding value for 13 out of 50 fragments is in the [-2.48, -
0.83] Kcal/mol range (see Table S2). Interestingly, 12 out of 13 of
these fragments bind at the locations of three of the sites of our
structure-based common pharmacophore (i.e., H/R1, H/R2 and
H/R4), whereas the remaining fragment is close to the H/R1 site
(see Table S2). These findings demonstrate that our pharmaco-
phore is able to capture all of the essential features for an inhibitor
interaction with the DPP-IV binding-site, which would explain
why all of the assayed molecules show activity as DPP-IV
inhibitors (see Figure 6). Moreover, the analysis in Table S2
shows that C5 activity can be improved if (1) its butyl group
matching the H/R1 site is replaced by a group that is able to
interact with the lipophilic atoms of the S1 pocket either by
producing the so-called hydrophobic enclosure reward (that would
consist of enclosing the two sides of the substituent –at a 180u
angle– on the hydrophobic environment of the S1 pocket) or by
making p-cation interactions with the aromatic side chains in this
pocket and (2) groups that match the H/R2 site (optional in our
pharmacophore but present in half of the ligands used to derive
the pharmacophore; see Table 2) and that are able to make
hydrophobically packed correlated H-bonds are added to C5.
The substituents that were attached to the C5 core to obtain the
top five derivatives with the highest predicted binding affinity for
the DPP-IV binding site are shown in Table S3. None of the five
molecules are currently registered in ChemSpider (http://www.
chemspider.com), whereas their analysis with FAF-Drugs2 shows
that all of these derivatives exhibit the proper ADMET properties.
Therefore, these derivatives are undescribed drug-like molecules
that, according to their XP GScores (see Table S3), would show
a significant increase in their binding affinity relative to C5 (i.e., -
4.2 Kcal/mol).
Figure 9 shows the docked poses for C5 derivatives compared
with C5 and can be used to explain the structural basis of the
expected increase in binding affinity. Remarkably, the XP
GScores for these poses are in the -9.5 to -11.8 Kcal/mol range
(see Table S3), whereas the GScores for the experimental poses of
the DPP-IV inhibitors shown in Figure 1 are in the -5.8 to -
11.0 Kcal/mol range (results not shown). Therefore, the C5
derivatives reported in Table S3 are likely to exhibit nanomolar
activity as DPP-IV inhibitors.
As shown in Figure 9, the C5 derivatives usually maintained the
most important protein-ligand interactions found for the C5 core.
Moreover, Table S3 also shows that all of the substituents that
Figure 4. Schematic overview of the VS workflow and the procedure used for selecting the VS hits that were tested for DPP-IV
inhibitory activity. For the VS, the number of compounds that passed each step and the programs used are showed. For the selection of VS hits for
bioactivity testing, the numbers show either how many VS hits are scaffold-hopping candidates for DPP-IV inhibition (Fingerprint similarity analysis
step) or how many molecules were experimentally tested for bioactivity (Biological test step).
doi:10.1371/journal.pone.0044971.g004
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have replaced the original C5 butyl group (i.e., at the H/R1 site)
have a common positive formal charge that, according to results
shown in Figure 9, allows them to form p-cation interactions with
two of the aromatic residues in the S1 pocket (i.e., Tyr662 and
Tyr666). Additionally, some of the substituents at this location (i.e.,
97 in C5-97-786, 100 in C5-100-563 and 274 in C5-274-536;
see Table S3) also aid in increasing the protein-ligand binding
affinity by enclosing the two sides of the corresponding ring in the
lipophilic protein environment in the S1 pocket (results not
shown). Furthermore, all substituents at the H/R2 site (except the
one in C5-309-787) are able to make hydrogen bonds either with
the S2 pocket residue Arg358 (i.e., 786 in C5-97-786, 784 in C5-
137-784 and 563 in C5-100-563; see Figures 9B, 9C and 9D) or
with Arg669 (i.e., 536 in C5-274-536; see Figures 9F). The 786
substituent in C5-97-786 is also able to make a hydrogen bond
with the Ser209 side chain (see Figure 9B). Remarkably, there are
SAR studies with a structurally distinct series of DPP-IV inhibitors
that show (1) a 4-fold loss of potency when substituents that
interact with the side chains of Ser209 and Arg358 are removed
[28], (2) a 2-fold increase in inhibition when a carboxylic acid that
interacts with Arg358 is introduced [27], and (3) a 6-fold increase
in inhibition when a 3-pyridyl group that interacts with Ser209 is
introduced [29]. Therefore, the substituents selected for the H/R2
site by the combinatorial screen are able to form the in-
termolecular interactions with the S2 pocket that previous SAR
studies with anti-diabetic drugs have shown to increase the affinity
for the DPP-IV binding site.
Conclusions
The challenge of any VS protocol consists of using in silico tools
to predict which molecules in a database have the required activity
against a specific target. The results of the present study
demonstrate that our VS protocol is highly successful in the
non-trivial identification of DPP-IV inhibitors with no chemical-
structure similarities to known activities. Therefore, scaffold
hopping on this target can be achieved. Moreover, this is the
first time that anti-diabetic activity has been described for C1 (i.e.,
ZINC00171758), C2 (i.e., ZINC01833887), C3 (i.e.,
Figure 5. Chemical structures and ZINC codes for the 9 molecules selected for experimentally testing whether these compounds
exhibited DPP-IV inhibitory activity. The insolubility of C4 and C6 prevented these compounds from being assayed for DPP-IV inhibitory
activity. Positions in the C5 structure that will be replaced by substituents to identify derivatives with higher binding affinity on the DPP-IV binding
site are (a) indicated with a grey background and (b) annotated with the label of the corresponding site in the common structure-based
pharmacophore (see Figure 3).
doi:10.1371/journal.pone.0044971.g005
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ZINC02091906), C5 (i.e., ZINC02132035), C7 (i.e.,
ZINC02113150), C8 (i.e., ZINC00518468) and C9 (i.e.,
ZINC02131242).
Although the IC50 of the 7 hit molecules indicates their in vitro
activity is significantly lower than that of most known DPP-IV
inhibitors used to derive the structure-based common pharmaco-
phore (see Figure 1), it is important to remark that these molecules
can be used as lead compounds for developing more potent
inhibitors by means of SAR studies. Furthermore, these 7
molecules were selected based on their commercial availability,
cost and purity with the primary goal of testing the performance of
our VS protocol. Therefore, it is possible that there are other
molecules among the remaining 210 molecules in clusters 10, 29,
30, 36, 37, 38, 40, 41, 44, 45, 49 and 50 (see Table S1) that could
be better starting points than C5 for the rational drug design of
potent and selective DPP-IV inhibitors with new chemical
scaffolds. Remarkably, our work makes a significant contribution
to the discovery of DPP-IV inhibitors of natural origin (described,
at present, for only few NPs [21,30–32]) from a quantitative point
of view. Moreover, this work is also applicable to screen synthetic
molecules databases when looking for antidiabetic activity.
Finally, we would like to note the high degree of agreement
between our predictions (without making any prior knowledge-
based assumptions that could bias our decisions) about the
derivatization of C5 to increase the binding affinity (e.g.,
introducing side chains that could interact with Ser209 and
Arg358) and what SAR studies have reported in the literature for
achieving this increase. Therefore, this strongly supports the
reliability of our combinatorial screening results.
Methods
Criteria for Selecting the 3D Structures for DPP-IV
Complexes used to Derive the Common Structure-based
Pharmacophore
Coordinates for complexes between DPP-IV and potent re-
versible inhibitors were obtained from the PDB with the help of
the following information: (a) LigPlot [33] schemes downloaded
from the PDBsum website (http://www.ebi.ac.uk/pdbsum/) that
were used to confirm the non-peptide and reversible character of
the DPP-IV inhibitor present in each complex and; (b) IC50 values
directly extracted from the literature describing the complexes
(only complexes with inhibitors with IC50#10 nM were consid-
ered). Furthermore, the complexes with at least one mutation in
their amino acid sequences were discarded. The reliability of the
binding-site residues and inhibitor coordinates was assessed for the
remaining complexes by visually inspecting their degree of fitness
to the corresponding electron density map available from the
Uppsala Electron Density Server (EDS; http://eds.bmc.uu.se/
eds/) [34].
Superposition of the Selected DPP-IV Structures
The coordinates from the PDB complexes that met all the
mentioned requirements were superposed with the DeepView v3.7
program (http://spdbv.vital-it.ch/) [35] to have the complexes in
the same relative orientation. Only the resulting re-oriented
coordinates for these PDB files were used during the subsequent
structure-based pharmacophore generation and in the steps of the
VS workflow (i.e., pharmacophore-based searches, protein-ligand
Figure 6. Dose-response results for the in vitro inhibition of DPP-IV by C1, C2, C3, C5, C7, C8 and C9. The relative DPP-IV inhibitory
activity with or without the selected NPs (vehicle, 1% DMSO) is shown where each column represents the average 6 SEM (n = 3 or 4). The insolubility
of C5, C7 and C9 in DMSO at 1 mM prevented the measurement of DPP-IV inhibitory activity. *p,0.05 **p,0.1 vs vehicle, T-student.
doi:10.1371/journal.pone.0044971.g006
Figure 7. DPP-IV inhibitory dose-response curve obtained for
C5 via a competitive binding assay.
doi:10.1371/journal.pone.0044971.g007
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docking studies and shape and electrostatic-potential comparisons)
where spatial orientation is crucial.
Common Structure-based Pharmacophore for DPP-IV
Inhibition
Energetic structure-based pharmacophores were built from
the superposed coordinates of the previously selected complexes
by means of the Glide-based procedure developed by Schro¨-
dinger (Schro¨dinger LLC., Portland, USA; http://www.
schrodinger.com) [36]. According to this procedure, pharmaco-
phore sites are ranked based on the Glide XP energies with the
advantage that each contribution to the protein-ligand interac-
tions is quantified. Therefore, energetically favorable features
can be incorporated into the pharmacophore with preference
over energetically weaker features. The resulting individual
energetic pharmacophores were used for the construction of
a common structure-based pharmacophore for DPP-IV re-
versible inhibition. This pharmacophore consists on two
compulsory sites (one positive/donor and one hydrophobic/
aromatic ring) whereas the remaining acceptor and hydropho-
bic/aromatic ring sites are optional. The associated tolerances
for the different sites are 1.8A˚ for P/D, A1 and A2, 2.0A˚ for
H/R1, H/R3 and H/R4 and 3.3A˚ for H/R2. The
pharmacophore was completed with receptor-based excluded
volumes that schematically represent the location of the DPP-IV
residues that form the binding pocket by applying the
Receptor-Based Excluded Volumes graphic front-end from
Phase v3.1 (Schro¨dinger LLC., Portland, USA; http://www.
schrodinger.com) [37] to the PDB file 3C45. The Sphere
filters parameter values were set to the following criteria: (a)
ignoring receptor atoms whose surfaces were within 0.25 A˚ of
ligand surface; and (b) limit excluded volume shell thickness to
10 A˚. Otherwise, the remaining parameter values used were the
default values.
Ligand Selection for VS Purposes
Ligands for VS purposes were downloaded from the Natural
Products subset of the ZINC database (http://wiki.bkslab.org/
index.php/Natural_products_database) [19]. This dataset con-
tains 89,165 commercially available natural products and natural-
product derivatives, making the dataset suitable for experimentally
testing the success of a VS workflow.
ADME/Tox Filter
The ADME/Tox filter was carried out with the FAF-Drugs2
tool [23]. The drug-like properties of a compound were evaluated
using the Lipinski rule [38]. The Lipinski rule is based on a set of
property values, such as the number of hydrogen-bond donors and
acceptors, the molecular weight and the logP, that were derived
from drugs with good ADME characteristics. Molecules that
Figure 8. Docking poses for C1, C2, C3, C7, C8 and C9 at the 3C45 binding site. All of the panels in this figure and in Figure 9 are in the
same relative orientation to allow for easier comparisons between the predicted poses. Residues at the DPP-IV binding site are colored according to
the subsite where they belong (i.e., residues from the S1 pocket are colored in cyan, those from the S2 pocket are red and those from the N-terminal
recognition region are green). Other important residues that have not been classified in any pocket are colored in white. Dashed lines are used to
show intermolecular hydrogen bonds (in red) or charge-charge interactions (in blue).
doi:10.1371/journal.pone.0044971.g008
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adhere to the Lipinski rule are expected to be active in humans
after oral admission. Only one violation of this rule was allowed.
Molecules containing toxic groups were filtered using the 204
substructures for ‘‘warhead’’ chelators, frequent hitters, pro-
miscuous inhibitors and other undesirable functional groups
available in the FAF-Drugs2 tool [23].
Ligand Setup
The 3D structures of the ligands for VS purposes were
incorporated into LigPrep v2.3 (Schro¨dinger LLC., Portland,
USA; http://www.schrodinger.com) and improved by cleaning.
The cleaning process was carried out using the following
parameters: (a) the force field used was OPLS 2005; (b) all
possible ionization states at pH 7.062.0 were generated with
Ionizer; (c) the desalt option was activated; (d) tautomers were
generated for all ionization states at pH 7.062.0; (e) chiralities
were determined from the 3D structure; and (f) one low-energy
ring conformation per ligand was generated. Conformations and
sites for the resulting ligand structures were determined during the
generation of the corresponding Phase [37] databases with the
Generate Phase Database graphic front-end. Default param-
eter values were used during this conformer generation with the
exception of the maximum number of conformers per structure,
which increased from 100 (the default value) to 200. The
conformer sites were generated with definitions made by adding
the ability to consider aromatic rings as hydrophobic groups to the
default built-in Phase definitions.
Structure-based Pharmacophore Screening
The initial filtering through the structure-based common
pharmacophore was performed with Phase v3.1 using the
following steps: (a) search in the conformers database, (b) do not
score in place the conformers into the structure-based common
pharmacophore (i.e., allow reorientation of the conformers to
determine if they match the pharmacophore or not), (c) match the
two compulsory sites of the structure-based common pharmaco-
phore and at least one of the optional sites, (d) do not have
a preference for partial matches involving more sites and (e) use
the excluded volumes from the structure-based common pharma-
cophore. Default values were used for the rest of the options and
parameter values used during this search. For the second
pharmacophore screening, the same filtering options of the first
pharmacophore matching were applied with the exception that
now no re-orientation of the poses was allowed during the search
(i.e., the score in place option was used) because it was performed by
using docked poses.
Protein-ligand Docking during the VS
During the VS, the protein-ligand docking was performed with
eHiTS v2009 (SimBioSys Inc., Toronto, Canada; http://www.
simbiosys.ca/ehits) [39], and ligands were docked into the ligand
Figure 9. Docked poses for C5 (panel A) and the five C5 derivatives with the highest predicted affinities (panels from B to F) at the
3C45 binding site. All of the panels in this figure and in Figure 8 are in the same relative orientation to allow for easier comparisons between the
predicted poses. Residues at the DPP-IV binding site are colored by the same criteria described in Figure 8. Dashed lines are used to show
intermolecular hydrogen bonds.
doi:10.1371/journal.pone.0044971.g009
Novel Human DPP-IV Inhibitors of Natural Origin
PLOS ONE | www.plosone.org 10 September 2012 | Volume 7 | Issue 9 | e44971
binding site of the DPP-IV conformation present in the 3C45 PDB
file [14]. The receptor was considered to be a rigid body and the
ligands as flexible such that free rotation was allowed around the
single bonds of the ligand. Default docking conditions were
selected with the exception of the size of the sides of the cubic box
encompassing the DPP-IV binding site, which was increased from
10 A˚ to 15 A˚.
Electrostatic and Shape Similarity Screening
The software EON v2.0.1 (OpenEye Scientific Software, Inc.,
Santa Fe, New Mexico, USA; http://www.eyesopen.com) deter-
mines the electrostatic potentials of two compounds and
consequently calculates the Electrostatic Tanimoto combo score
(ET_combo). The ET_combo is the sum of the Shape Tanimoto
(ST) and the Poisson-Boltzman Electrostatic Tanimoto scores. The
Shape Tanimoto (ST) score is a quantitative measure of three-
dimensional overlap where 1 corresponds to a perfect overlap (i.e.,
the same shape) [40]. The Poisson-Boltzman Electrostatic
Tanimoto score (ET_pb) compares the electrostatic potential of
two small molecules where 1 corresponds to identical potentials
and negative values correspond to the overlap of positive and
negative charges [41]. Only those molecules that have both
ET_pb and ST score values higher than 0.623 and 0.244,
respectively, were selected and visualized with VIDA v4.0.3
(OpenEye Scientific Software, Inc., Santa Fe, New Mexico, USA;
http://www.eyesopen.com). These threshold values were chosen
after analyzing which ET_pb and ST score values are obtained
when the DPP-IV inhibitor in PDB file 3C45 is compared with the
experimental poses of the rest of the inhibitors from which the
common pharmacophore was derived (see Figure 1).
Hit Selection for Further Experimental Assays on DPP-IV
Activity
The molecules that survived the electrostatics/shape similarity
filter were merged with 2,342 known inhibitors obtained from the
BindingDB database [24], and then clustered using Canvas v1.2
(Schro¨dinger LLC., Portland, USA; http://www.schrodinger.
com). MOLPRINT2D fingerprints [42], using a fingerprint pre-
cision of 32 bits, were calculated for each molecule and then
hierarchical clustering, based on Tanimoto similarities, was
performed resulting in 50 clusters. Nine compounds from 7 of
the 12 clusters exclusively formed by NPs that were previously
unidentified as DPP-IV inhibitors were selected based on their
commercial availability, cost and purity ($92%) for in vitro assays
of DPP-IV inhibitory activity. These compounds were
ZINC00171758 (i.e., C1), ZINC01833887 (i.e., C2),
ZINC02091906 (i.e., C3), ZINC02118100 (i.e., C4),
ZINC02132035 (i.e., C5) and ZINC02160434 (i.e., C6),
ZINC02113150 (i.e., C7), ZINC00518468 (i.e., C8) and
ZINC02131242 (i.e., C9), which were all purchased from
InterBioScreen, Ltd (http://www.ibscreen.com).
In vitro Assay of the Effect of Selected Compounds on the
DPP-IV Activity
The DPP-IV Drug Discovery Kit-AK499 (Enzo Life Sciences
International, Inc.) was used to conduct DPP-IV inhibition assays.
Briefly, 10 mL of each compound were added to commercial
recombinant human DPP-IV. Stock solutions of the assayed
compound were made in DMSO and diluted in buffer (50 mM
Tris-HCl) to final concentrations ranging from 10–1000 mM in the
assay. The final concentration of DMSO in the assay was 1%.
After 10 minutes of incubation at 37uC, the reaction was initiated
by the addition of the fluorimetric substrate H-Gly-Pro-AMC.
Fluorescence was measured continuously for 30 minutes at Ex:
380 nm/Em: 460 nm in a Biotek FLx800 Fluorescence Micro-
plate Reader. At least three independent assays were performed,
each with two technical replicates. A standard DPP-IV inhibitor
(P32/98 from Biomol, Germany) served as positive control.
IC50 Calculation
IC50 was determined using GraphPad Prism v4.0 for Windows
(GraphPad Software, San Diego CA, USA; http://www.
graphpad.com) by fitting the experimental data from the in vitro
assay to a nonlinear regression function using a four-parameter
logistic equation.
Docking of Novel DPP-IV Ligands
Docking studies of DPP-IV inhibitors C1, C2, C3, C5, C7, C8
and C9 were performed with the software Glide v5.6 (Schro¨dinger
LLC., Portland, USA; http://www.schrodinger.com) using the
DPP-IV coordinates that can be found using the 3C45 PDB code.
The binding site was defined using the default options of the
Receptor Grid Generation panel. Standard-precision (SP) docking was
initially used to screen the ligands. The flexible docking mode was
selected such that Glide internally generated conformations during
the docking process. No constraints were selected for docking.
Each docking run recorded at most ten poses per ligand that
survived the post-docking minimization. The best docking poses
for the novel DPP-IV ligands were selected by not only
considering the docking scores but also by taking into account
the results of the visual inspection of all docking poses. This
visualization was performed with Maestro v9.2 (Schro¨dinger
LLC., Portland, USA; http://www.schrodinger.com). Further,
the location of the selected poses within the binding site was
refined with extra-precision (XP) to maximize the intermolecular
interactions between C1, C2, C3, C5, C7, C8 and C9 and the
DPP-IV binding site. The resulting C5 docked pose was
subsequently used for lead-optimization.
Lead-optimization from the Most Active Compound
Improvement of the binding affinity of C5 was performed in
two steps. Initially, a library formed by 50 fragments (and available
with the last version of the Schro¨dinger suite) was docked at the
3C45 binding site using the Glide XP mode. Then, the XP
visualizer tool (Schro¨dinger LLC., Portland, USA; http://www.
schrodinger.com) was used to compare the values for the different
XP descriptors between the C5 docked pose and the highest score
pose for each fragment. We focused the comparisons on XP
descriptors that have no contributions to the XP GScore of C5 but
instead show significant values for some fragments (i.e., the
PhobEn, PhobEnHB, PhobEnPairHB and pCat descriptors;
see Table S2). This comparison resulted in potential attachment
positions of C5 for testing substituents that could improve the
DPP-IV inhibitory activity by increasing the corresponding affinity
for the target.
The substituents available in the CombiGlide Diverse Side-
chain Collection v1.2 (which contains all reasonable ionization
and tautomeric states for a collection of 817 representative
functional groups commonly found in pharmaceuticals, with
linkers of variable lengths) were used to replace the original
substituents of C5 at each attachment point (see Figure 5). This
replacement was carried out using the Virtual Combinatorial
Screening workflow available in CombiGlide v2.7 (Schro¨dinger
LLC., Portland, USA; http://www.schrodinger.com). During the
docking step of this workflow, docked poses were restricted to be
within a maximum RMSD of 1.0 A˚ relative to the C5 core in the
C5 predicted pose (see Figure 9A). Moreover, those C5 derivatives
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resulting from a single substitution at any position on the core
structure were docked, and those reagents at each position that did
not seem promising were screened out. This elimination
significantly reduced the number of fully substituted structures to
be docked. The remaining options during the combinatorial
screening were set by default. Finally, the top 100 scored poses for
the C5 derivatives were selected for refinement with Glide XP
using the default options, and the resulting top-five ranked poses
were chosen for further analyses (see Table S3).
Supporting Information
Table S1 Predicted scaffold-hopping candidates for
DPP-IV inhibition. This table shows ZINC codes for the 219
hit molecules predicted to inhibit DPP-IV that belong exclusively
to clusters containing NPs that were previously unidentified as
DPP-IV inhibitors. The best results of the shape and electrostatic-
potential comparisons for each hit molecule with the ligand of
3C45 crystallized structure are shown. The Tanimoto values for
the comparison between the electrostatic potentials of the
molecules (using an outer dielectric of 80) are shown in the
ET_PB columns. Furthermore, the values for the comparison
between shapes are shown in the ET_Shape columns. The sum of
the ET_PB and ET_Shape values is reported in the Combo
columns. Hits from each cluster are sorted according to their
decreasing combo value. ZINC00171758 and ZINC01833887
(cluster 30), ZINC02091906 (cluster 36), ZINC02118100 (cluster
37), ZINC02132035 and ZINC02160434 (cluster 41),
ZINC02113150 (from cluster 45), ZINC00518468 (cluster 49)
and ZINC02131242 (cluster 50) were tested in an in vitro assay to
validate the success rate of our predictions (in bold in Table S1).
Due to the insolubility, ZINC02118100 (cluster 37) and
ZINC02160434 (cluster 41) could not be tested.
(PDF)
Table S2 Docked fragments that have significant con-
tributions to the GScore for XP descriptors that are
0.00 Kcal/mol for C5. The most potent DPP-IV inhibitor
found by our dose-response studies (i.e., C5) has no contribution to
the GScore by the following XP descriptors: (a) PhobEn (i.e.,
hydrophobic enclosure reward); (b) PhobEnHB (i.e., reward for
hydrophobically packed H-bond); (c) PhobEnPairHB (i.e., reward
for hydrophobically packed correlated H-bond); and (d) pCat (i.e.,
reward for p-cation interactions). This table displays the docked
fragments showing the highest values for these XP descriptors and
the common pharmacophore sites of Figure 3 that are matched to
the corresponding fragment, if any.
(DOC)
Table S3 Top five C5 derivatives according to their XP
GScores. The top five C5 derivatives according to their
XP GScore values. The structures of the substituents that were
attached to the C5 core at the two replacement sites (see Figure 5)
are shown. The code for each molecule is obtained by adding the
CombiGlide Diverse Side-chain Collection code for the substi-
tuents at the H/R1 and at the H/R2 sites to C5.
(DOC)
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